EUCTR2004-000701-21-AT进行中（未招募）不适用
A phase 2, double-blind, randomized, placebo-controlled, multi-center study assessing the value of adding RAD001 to letrozole (Femara®) as preoperative therapy of primary breast cancer in postmenopausal women - N/A
ovartis Services AG0 个研究点目标入组 212 人开始时间: 2004年10月21日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 212
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Adult female patients (=18 years old)
- •Histologically-confirmed diagnosis of invasive breast cancer, previously untreated (patients who have been treated for cancer of the contralateral breast can be included if there is at least a 2 year time interval from last systemic treatment for breast cancer before randomization into this study)
- •Patients must be postmenopausal as defined by any of the following criteria:
- •1. Radiation induced menopause or surgical bilateral oophorectomy
- •2. Women with an intact uterus and
- •= 55 years of age or
- •< 55 years of age without menses for the last 5 years or
- •< 55 years of age and has not had menses for at least the last 12 months (but has had menses in the last 5 years) and has postmenopausal levels of FSH (according to the postmenopausal range of the individual laboratory, and performed at least four weeks after stopping HRT/oral contraceptives)
- •3. Women without an intact uterus and
- •= 55 years of age or
- •< 55 years of age and postmenopausal levels of FSH (according to the postmenopausal range of the individual laboratory, and performed at least four weeks after stopping HRT/oral contraceptives)
- •Candidates for mastectomy or breast-conserving surgery
- •Primary tumor of above 2 cm diameter, measured by imaging
- •Primary tumor is ER positive, defined as: = 10% of the nuclei in the invasive component of the tumor stain positive after immunostaining (analyzed in local laboratory)
- •Clinical Stage M0 (bone scan, chest X-ray and abdominal CT scan or liver ultrasound required at screening to exclude metastatic disease)
- •WHO performance status = 1
- •Adequate bone marrow function as shown by: WBC =3.5 x 109/L, ANC = 1.5 x 109/L, Platelets = LLN, Hb >10g/dL
- •Adequate liver function as shown by: serum bilirubin = 1.5 x ULN, albumin = 3 g/dl, serum transaminases activity = 2.5 x ULN, alkaline phosphatase = 2.5 x ULN
- •Normal renal function (serum creatinine = 1.5 x ULN, BUN = 1.5 x ULN)
- •Signed consent to participate in the study must be obtained from patients after they have been fully informed on the nature and potential risks by the investigator with the aid of written information.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients with multifocal invasive tumors
- •Patients with bilateral or inflammatory breast cancer (a bilateral mammography is required at screening visit)
- •Patients receiving concomitant anti-cancer treatments such as chemotherapy, immunotherapy/biological response modifiers (BRMs), endocrine therapy (including steroids), and radiotherapy. Patients who have received hormone replacement therapy will NOT be excluded, provided that HRT is discontinued at least 2 weeks prior to entry into the study (i.e. 2 weeks prior to screening assessments).
- •Known hypersensitivity to everolimus or sirolimus (rapamycin), to letrozole or lactose (contained in formulations of RAD001 and letrozole)
- •= grade 3 hypercholesterolemia/ hypertriglyceridemia or = grade 2 hypercholesterolemia/ hypertriglyceridemia with history of coronary artery disease (despite lipid-lowering treatment if given)
- •Patients with an uncontrolled infection
- •Patients with other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study (i.e., uncontrolled diabetes mellitus, uncontrolled cardiac disease (unstable angina), uncontrolled hypertension, congestive cardiac failure, ventricular arrhythmias, active ischemic heart disease, myocardial infarction within six months, chronic liver or renal disease, active upper GI tract ulceration)
- •Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.
- •Patients with a history of noncompliance to medical regimens
- •Patients unwilling or unable to comply with the protocol (especially: 15-day biopsy, necessity to undergo breast surgery despite a clinical complete response)
- •Patients who received any other investigational drugs within the 30 days prior to the screening visit
- •Patients being treated with drugs recognized as being strong inhibitors or inducers of the isoenzyme CYP3A (Rifabutin, Rifampicin, Clarithromycin, Ketoconazole, Itroconazole, Voriconazole, Ritinavir, Telithromycin) within the last 5 days
研究者
相似试验
进行中（未招募）
1 期
A study to investigate the possible interaction between clobazam and cannabidiol.MedDRA version: 18.1 Level: PT Classification code 10073677 Term: Severe myoclonic epilepsy of infancy System Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2014-002942-33-GBGW Research Ltd20
进行中（未招募）
1 期
Drug-drug interactions between stiripentol or valproate and GWP42003-P in patients with epilepsyEpilepsyMedDRA version: 18.1 Level: PT Classification code 10073677 Term: Severe myoclonic epilepsy of infancy System Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2015-002939-18-ESGW Research Ltd.40
进行中（未招募）
1 期
A study to investigate the possible interaction between clobazam and cannabidiol.MedDRA version: 18.1Level: PTClassification code 10073677Term: Severe myoclonic epilepsy of infancySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEpilepsyEUCTR2014-002942-33-ESGW Research Ltd20
已完成
2 期
A phase 2, double-blind, randomized, placebo-controlled pharmacokinetic trial in two parallel groups to investigate possible drug- drug interactions between stiripentol or valproate and GWP42003-P in patients with epilepsy.epilepsyNL-OMON44208GW Research Ltd6
进行中（未招募）
1 期
Drug-drug interactions between stiripentol or valproate and GWP42003-P in patients with epilepsyMedDRA version: 20.0Level: PTClassification code 10073677Term: Severe myoclonic epilepsy of infancySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEpilepsyEUCTR2015-002939-18-PLGW Research Ltd.34